The blood–brain barrier (BBB) greatly restricts the entry of biological and engineered therapeutic
molecules into the brain. Due to challenges in translating results from animal models to …

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling
protein in tumours 1 , 2 . The KRAS(G12C) mutant has a cysteine residue that has been …

Helicobacter hepaticus-infected Rag2 -/- mice emulate many aspects of human inflammatory
bowel disease, including the development of colitis and colon cancer. To elucidate …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
with potential resistance to existing drugs emphasizes the need for new therapeutic …

Inflammatory bowel disease (IBD) arises from inappropriate activation of the mucosal
immune system resulting in a state of chronic inflammation with causal links to colon cancer. …

Recent therapeutic success of large-molecule biologics has led to intense interest in assays
to measure with precision their transport across the vascular endothelium and into the target …

Diclofenac, a nonsteroidal anti-inflammatory drug, is metabolized to a reactive acyl glucuronide
that has been proposed to mediate toxic adverse drug reactions associated with its use. …

In vitro prediction of physiologically relevant transport of therapeutic molecules across the
microcirculation represents an intriguing opportunity to predict efficacy in human populations. …

Protein S-nitrosation on cysteine residues has emerged as an important posttranslational
modification in mammalian cells. Previous studies have suggested a primary role for …

Diclofenac, a nonsteroidal anti-inflammatory drug, is metabolized to diclofenac-1-O-acyl
glucuronide (D-1-O-G), a chemically reactive conjugate that has been implicated as playing a …